BPC-157 vs NAD+

Recovery

Metabolic

Under 2026 FDA Review

Research Only

Preclinical studies suggest BPC-157 promotes angiogenesis and granulation tissue formation, with reported upregulation of VEGFR2 signaling and activation of the FAK-paxillin pathway in tendon fibroblasts. It has also been reported to modulate the nitric oxide system and interact with dopaminergic and serotonergic pathways along the gut-brain axis. A precise receptor target has not been established.

NAD+ functions as a primary electron carrier in glycolysis, the TCA cycle, and oxidative phosphorylation. Beyond its redox role, NAD+ serves as a consumable substrate for sirtuin deacetylases (SIRT1-7), poly(ADP-ribose) polymerases (PARPs), and CD38/CD157 ectoenzymes. Sirtuin activation is linked to mitochondrial biogenesis, autophagy, and stress-response gene expression, and PARP activity is central to DNA-damage repair. Oral bioavailability of intact NAD+ is poor, which is why clinics market IV infusion; the best human data for raising tissue NAD+ involve oral precursors NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) rather than NAD+ itself.

250–500 mcg (community-reported, not clinically validated)

IV 500-1500mg per session; SubQ 100-200mg

SubQ or Oral

IV, SubQ